TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Average PT from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $40.67.

A number of research firms have recently weighed in on TGTX. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $37.35 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a fifty day simple moving average of $35.27 and a 200 day simple moving average of $30.85. TG Therapeutics has a 12-month low of $12.93 and a 12-month high of $43.32. The company has a market cap of $5.87 billion, a P/E ratio of -373.46 and a beta of 2.13.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Sell-side analysts predict that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Trading of TG Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after purchasing an additional 209,190 shares during the last quarter. State Street Corp grew its holdings in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after purchasing an additional 2,398,015 shares during the period. Soleus Capital Management L.P. increased its position in TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after buying an additional 146,702 shares during the last quarter. Clearbridge Investments LLC bought a new stake in shares of TG Therapeutics in the fourth quarter valued at $55,237,000. Finally, Northern Trust Corp lifted its position in shares of TG Therapeutics by 8.6% during the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock valued at $46,141,000 after buying an additional 120,785 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.